Severe reduction in the β-cell number (collectively known as the β-cell mass) contributes to the development of both type 1 and type 2 diabetes. Recent pharmacological studies have suggested that increased pancreatic β-cell proliferation could be due to specific inhibition of adenosine kinase (ADK). However, genetic evidence for the function of pancreatic β-cell ADK under physiological conditions or in a pathological context is still lacking. In this study, we crossed mice carrying LoxP-flanked Adk gene with Ins2-Cre mice to acquire pancreatic β -cell ADK deficiency (Ins2-Cre ± Adk fl/fl ) mice. Our results revealed that Ins2-Cre +/-Adk fl/fl mice showed improved glucose metabolism and β-cell mass in younger mice, but showed normal activity in adult mice. Moreover, Ins2-Cre ± Adk fl/fl mice were more resistant to streptozotocin (STZ) induced hyperglycaemia and pancreatic β-cell damage in adult mice. In conclusion, we found that ADK negatively regulates β-cell replication in young mice as well as under pathological conditions, such as STZ induced pancreatic β-cell damage. Our study provided genetic evidence that specific inhibition of pancreatic β-cell ADK has potential for anti-diabetic therapy.
| INTRODUC TI ON
Both type 1 and type 2 diabetes ultimately result from the failure of pancreatic β-cell functions, including either a reduced β-cell mass or insufficient insulin secretion in response to high blood glucose. [1] [2] [3] [4] [5] [6] However, the β cells of human islets have a very short proliferation window, which normally ends after childhood. 5, [7] [8] [9] [10] Therefore, diabetes patients normally cannot compensate for islet β-cell loss and there is great interest in searching for pharmacological reagents to increase β-cell proliferation under different diabetic pathological conditions. 4, 5, 11 Recently, using the high-throughput primary β-cell proliferation assay, two adenosine kinase (ADK) inhibitors (5-IT) and ABT-702 were shown to effectively improve β-cell replication. 11 Additionally, a study has shown that 5-IT might increase the β-cell mass through non-specific inhibition of dual-specificity tyrosine phosphorylation-regulated kinase-1A (DYRK1A) and glycogen synthase kinase 3 beta (GSK3B). Furthermore, it was demonstrated that specific blockade of DYRK1A increases pancreatic β-cell proliferation. 4, 5 Although these studies demonstrated that specific inhibition of kinase in pancreatic β cells have the potential to effectively treat diabetes by inducing pancreatic β-cell proliferation, genetic evidence is urgently needed to confirm the specific role of each kinase in β-cell proliferation in different pathological processes and help in the precise and rational design of anti-diabetic therapies.
As the first kinase target identified through high-throughput screening for pancreatic β-cell proliferation, ADK is a purine ribonucleoside kinase that converts adenosine to adenosine monophosphate. Adenosine kinase is ubiquitously expressed, and studies of its functional role are normally achieved by specific ablation of its gene in different tissues. [12] [13] [14] [15] [16] [17] Therefore, in this study, we specifically 
| RE SULTS

| Age-dependent decrease in ADK expression in pancreatic islets
Previous studies have shown that inhibition of the kinase activity of ADK leads to pancreatic β-cell replication in isolated islets, suggesting that it is an important regulator of pancreatic β-cell homeostasis.
To characterize the temporal expression of ADK in islets, we measured the expression levels of ADK at the ages of 1, 2, 3, 4, 8, and 12 weeks. Both the mRNA and protein levels of ADK were lower in islets of 1 and 2-week-old mice, while higher expression was noted at the age of 4 weeks, and gradual decrease in expression was observed at the age of 8 weeks ( Figure 1A -C).
| ADK ablation in pancreatic β cells improves glucose tolerance and β-cell function in mice
To study the ADK function in pancreatic β cells in vivo, we crossed Figure 2C ). Moreover, more insulin release was observed for isolated islets derived from Ins2-cre ± Adk fl/fl mice than their WT littermates in response to 20 mmol/L glucose stimulation ( Figure 2D ). To figure out if ablation of Adk in β cells may affect pancreatic alpha cell homeostasis, we measured the plasma glucagon concentration from Ins2-cre ± Adk fl/fl , Adk fl/fl and Ins2-cre ± mice and found no significant differences in the plasma glucagon concentration among the study groups ( Figure 2E ). Taken together, these results suggest that ADK deficiency in pancreatic β cells improves glucose tolerance in response to high glucose, likely due to the increased insulin content and secretion from pancreatic islets.
| ADK ablation induces β-cell proliferation and islet expansion
To explore the cellular mechanisms of increased insulin content and insulin secretion of pancreatic islets isolated from Ins2-cre ± Adk fl/fl mice, we first inspected the islet morphology and proliferation. We stained pancreatic sections with insulin and Ki67 antibodies, and found that the islets derived from Ins2-cre ± Adk fl/fl mice showed more Ki67 staining than islets derived from their WT littermates, suggesting more proliferation of pancreatic β cells in Ins2-cre ± Adk fl/ fl mice ( Figure 3A,B) . Consistently, the Ins2-cre ± Adk fl/fl mice have more pancreatic β cells in each islet statistically ( Figure 3C ). 
| Loss of ADK in a β-cell makes the islets more resistant to STZ
We then examined the role of ADK in pancreatic β cells under acute β-cell loss, using a STZ-induced type 1 diabetes model in adult mice (9-12 weeks). 19 Streptozotocin (100 mg/kg body weight), was in- 
| D ISCUSS I ON
There is a strong need to develop new therapeutic methods to increase the proliferation of pancreatic β cells while maintaining their normal identity and functions. 4 Recently, the screening of small compounds using a primary β-cell replication assay or a human MYC (transcriptional regulator Myc-like) expression system identified that inhibition of at least two kinase targets, ADK and DYRK1A, can compensate for β-cell loss during type 1 or type 2 diabetes. 4 However, 
| MATERIAL AND ME THODS
| Animal breeding and genotyping
The Cre driver Ins-2-Cre mice were bought from Jackson Laboratory as described previously. 26 The Adk fl/fl mice were provided by
Professor Yuqing Huo at Vascular Biology Center, Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University. 27, 28 All experiments were performed with male mice.
PCR-based genotyping for DNA extraction from tails was performed using standard methods. Tissue from mice was obtained by tail clipping or from specific organs. Genomic DNA was prepared following standard procedures. PCR products were loaded in 2% agarose gel dyed with ethidium bromide for band visualization.
| Islet isolation and Western blotting
Pancreatic islet isolation was performed as previously reported in our laboratory. 19, 26, [29] [30] [31] Briefly, 4-week-old mice were killed by cervical dislocation, and the pancreata were removed and in- 
| RNA extraction and quantitative reverse transcription-PCR
RNA from islets derived from Ins2-Cre ± Adk fl/fl mice as well as from their littermates WT control group was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) as described previously.
32,33
We performed cDNA synthesis using the qRT-PCR Kit (FSQ-101;
Toyobo) and conducted quantitative reverse transcription-PCR (qRT-PCR) using the Light Cycler qPCR apparatus (Bio-Rad) with Fast
Start SYBR Green Master (Roche).
| Islet insulin secretion assay and plasma glucagon measurement
Mouse islets were isolated from the Adk fl/fl , Ins2-Cre ± and Ins2-Cre ± Adk fl/fl groups (n = 5 mice, per group) and then divided into 30 islets for each sample, followed by culture in vitro overnight.
Next, the insulin secretion assay was performed as previously de- 
| Glucose tolerance test
Glucose tolerance tests were performed as previously described. 19, 26, 29 Three groups of mice were fasted 16 hours, and then the baseline (0 points) blood glucose levels were measured in samples taken from the tail vein. Next, glucose (2 g/kg body weight) in sterile PBS was injected intraperitoneally, and blood glucose was measured at serial times of 15, 30, 60 and 120 minutes after injection for the glucose tolerance test using a Free Style Lite Glucose Meter (Roche).
| Immunofluorescence
Immunofluorescence was performed as previously described. 32, 33, 36, 37 The mice were sacrificed by cervical dislocation, and the pancreata were immediately dissected, washed in PBS and # A-31572; Alexa Fluor 555; Invitrogen) or donkey anti-rat antibody (cat. #ab150154; Thermo Fisher). Finally, the slices were stained with 4,6-diamidino-2-phenylindole (DAPI 1:1000; Invitrogen), followed by three times washing with PBS, and the slides were subjected to fluorescence microscopy analysis. 35, 38 
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| Morphometric measurements
Immunostaining of insulin (green), glucagon (red), somatostatin (red) and Ki67 (red) was performed in pancreatic sections from Adk fl/fl , Ins2-Cre +/-and Ins2-Cre ± Adk fl/fl mice (Scale bar: 50 μm, n = 6 mice for each point; all sections were used from each mouse).
The calculation of the ratio of the β-cell area/exocrine area (through a convention called the relative β-cell volume) was performed as previously described. 39, 40 Slides from each case were examined using a Zeiss LSM 780 laser scanning inverted confocal microscope (Germany). The objective magnification used for the slide scanning was ×40. The analysis was performed by manual picture acquisition and cell counting. Image analysis was performed to quantify the total tissue area within this region, followed by the insulin-positive area to generate the ratio of insulin staining to the total pancreas area using ImageJ and Image-Pro Plus software. To calculate the β-cell number per islet, each islet was evaluated to obtain the total islet cross-sectional area and the cell number within this islet positive for insulin using Image J and Image-Pro Plus software. To calculate Ki67 + insulin + cell number, only Ki67 immunostaining colocalization with DAPI in the insulin + cell was counted (Tables 1&2). TA B L E 2 PCR primers for genotyping at 37°C, followed by washing and fixing with 4% paraformaldehyde.
| Quantification of islet-cell apoptosis
Then islets were impeded in OCT, and sliced (6 µm). The sections were evaluated with insulin immunostaining, and terminaldeoxynucleotidyl transferase-mediated 2′-deoxyuridine 5′-triphosphate nick-end labelling (TUNEL, Jiangsu KeyGEN Bio TECH Crop; Ltd., cat # KGA70613) was used for apoptosis examination. The apoptotic β-cell ratio to the total islet β-cell was calculated using Image ProPlus software. 41 
| S TATIS TIC AL ANALYS IS
All statistical analyses are represented as Mean ± SD. Statistical differences were determined by the two-tailed, paired Student's t test when only two sets of data were present or using one-way ANOVA in the case of data with more than two groups, followed by Dunnett's and Bonferroni's post hoc tests for multiple comparisons; using GraphPad Prism Software Inc (San Diego, CA).
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